| Ytd | 19.87% | |
| 1y | 74.31% |
| Open | 30.25 | Prev Close | 30.26 | Low | 30.07 | High | 30.64 | Mkt Cap | 6.29B |
| Vol | 1.49M | Avg Vol | 1.24M | EPS | -2.84 | P/E | N/A | Forward P/E | -11.08 |
| Beta | 0.84 | Short Ratio | 14.60 | Inst. Own | 54.65% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-09 | 50-d Avg | 38.58 | 200-d Avg | 31.85 | 1yr Est | 48.88 |
IMVT News
U.S. stock futures fell, with Dow futures down 450 points. Argenx sank 8.7% after a Sjögren’s trial
Applied Digital shares rise after Q1 revenue and loss beat estimates; Xiao-I and iPower lead gainers
Immunovant halts IMVT-1402 CLE trial after missing primary endpoints, driving IMVT and Roivant share
Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CL
On Thursday, Immunovant (NASDAQ:IMVT) discussed first-quarter financial results during its earnings
Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.75) per share which missed the analyst con
JP Morgan analyst Brian Cheng maintains Immunovant (NASDAQ:IMVT) with a Overweight and raises the
Citigroup analyst Samantha Semenkow maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the
Wall Street analysts changed outlook on top names. Guggenheim raised price target for IMVT, Piper Sa
Guggenheim analyst Yatin Suneja maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the pric
Truist Securities analyst Danielle Brill maintains Immunovant (NASDAQ:IMVT) with a Hold and raise
Immunovant (NASDAQ:IMVT) reported a Q4 loss of 73 cents/share, missing estimates of 60 cents. R&
B of A Securities analyst Jason Gerberry maintains Immunovant (NASDAQ:IMVT) with a Buy and raises
HC Wainwright & Co. analyst Douglas Tsao maintains Immunovant (NASDAQ:IMVT) with a Buy and ra
Immunovant Inc (NASDAQ: IMVT) shares are trading higher Wednesday despite posting a wider-than-expec
US stocks rise with Dow gaining 1% on Wednesday. The Nasdaq and S&P 500 also saw gains. Lowe'
TAT Technologies Ltd (TATT) reported better-than-expected Q1 results, sending shares up 11.7%. Other
Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.73) per share which missed the analyst con
Goldman Sachs analyst Corinne Johnson maintains Immunovant (NASDAQ:IMVT) with a Neutral and raise
Dow futures down 400 points, Alto Neuroscience shares dip 13.6% after Phase 2 trial results, other s
GSAT: 24% | Globalstar shares are trading higher following reports suggesting that Amazon is in disc
Amazon may acquire Globalstar Inc., shares soared in pre-market trading. Other gainers include Turbo
Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoin
Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expe
Gainers
Gainers Chardan NexTech Acquisition 2 Corp. (NASDAQ: CNTQ) shares surged 102.6% to close at $21.5
Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Mond
Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares climbed 50.7% to close at $2.11 on Thursday
Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares jumped 52% to $2.1325 after B of A Securiti
During Monday's trading, 1214 companies set new 52-week lows.
On Friday, 422 stocks made new 52-week lows.
Companies Reporting Before The Bell • Immunovant (NASDAQ:IMVT) is expected to report earnings fo
On Wednesday, 807 companies reached new 52-week lows.
During Wednesday's trading, 435 companies set new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
Wednesday's session saw 784 companies set new 52-week lows.
On Friday, 431 companies hit new 52-week lows.
On Monday, 671 companies achieved new lows for the year.